Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MORE
Cancer immunotherapy is regarded as the most important scientific breakthrough in the field of tumor treatment, and antibody therapy is the core of this breakthrough. Despite the great success in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies include novel antibodies that can recognize peptide/MHC complexes on the surface of tumor cells. TCR-like antibodies can perform specific and important anti-tumor immunity through several different molecular mechanisms. At present, TCR-like antibody therapy has been successful in melanoma, leukemia, breast, colon, and prostate cancer models, prompting researchers to seek further breakthroughs in this field.
Equipped with high-end technology and doctorate-level scientists, Creative Biolabs has long been a well-known service provider in the field of antibody development and cell therapy. After years of exploration, we have developed a comprehensive list of TCR antibody products targeting the peptide / MHC complex which would be promising targets for the engineered TCR-T cell therapy.
Advantages of TCR-like Antibodies Over Other Immunotherapies
The biggest advantage of TCR-like antibodies is their ability to target intracellular tumor antigens with minimal in vitro manipulation. TCR-T adoptive cell therapy can also target intracellular antigens, but requires a more complicated preparation process. In addition, the transduced antigen-specific TCR may not match the endogenous wild-type TCR because both TCRs are present in the same T cell. However, TCR-like antibodies are relatively easy to prepare and store, and can be used directly. Through the binding of the Fab region to the peptide/MHC complex, the Fc region of the TCR-like antibody can bind to the Fcγ receptor (FcγR) expressed by the patient's NK cells, monocytes or macrophages, and activate these cells to kill tumors.
Fig.1 Schematics of T cell receptor (TCR) and TCR-like receptor.
Please browse the target below to find the right product for you.
Associated Antigen Target
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
